Form 6-K ProQR Therapeutics N.V. For: Sep 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ProQR Therapeutics N.V. (PRQR) PT Raised to $21 at Chardan Capital Markets
September 5, 2018 2:42 PM EDTChardan Capital Markets analyst Keay Nakae raised the price target on ProQR Therapeutics N.V. (NASDAQ: PRQR) to $21.00 (from $9.00) while maintaining a Buy rating after the company reported positive interim data from its Phase 1/2 clinical trial of QR-110 in patients with Lebers Congenital Amaurosis 10 (LCA 10).
Nakae commented, "We maintain our BUY rating and are increasing our 12-month price target to $21.00: We continue to believe that ProQR has the potential to become a significant... More
